Galecto option deal doubles Bristol-Myers IPF portfolio

Bristol-Myers Squibb signed a deal worth up to $444m with Galecto Biotech that gives the US big pharma company an option to buy Galecto and adds a second idiopathic pulmonary fibrosis (IPF) drug to the BMS pipeline.